Clinical Trials Logo

Adenocarcinoma clinical trials

View clinical trials related to Adenocarcinoma.

Filter by:

NCT ID: NCT00487695 Completed - Barrett's Esophagus Clinical Trials

Confocal Endomicroscopy for Barrett's Esophagus

CEBE
Start date: April 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if confocal laser endomicroscopy (CLE) can improve detection of Barrett's esophagus, dysplasia, and early esophageal cancer.

NCT ID: NCT00478426 Completed - Clinical trials for Endometrial Adenocarcinoma

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Start date: April 30, 2007
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well sunitinib malate works in treating patients with endometrial cancer that has come back after a period of improvement (recurrent) or has spread to other places in the body (metastatic). Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00474812 Completed - Clinical trials for Stage IV Pancreatic Cancer

Dasatinib in Treating Patients With Metastatic Pancreatic Cancer

Start date: May 2007
Phase: Phase 2
Study type: Interventional

Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well dasatinib works in treating patients with metastatic pancreatic cancer.

NCT ID: NCT00466960 Completed - Clinical trials for Fallopian Tube Cancer

Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy

Start date: May 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Colony stimulating factors, such as sargramostim (GM-CSF), may stimulate the immune system in different ways and stop tumor cells from growing and may also increase the number of immune cells found in bone marrow or peripheral blood and help the immune system recover from the side effects of chemotherapy. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving GM-CSF together with paclitaxel albumin-stabilized nanoparticle formulation may be an effective treatment for ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. PURPOSE: This phase II trial is studying how well giving GM-CSF together with paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that did not respond to previous chemotherapy

NCT ID: NCT00466752 Completed - Clinical trials for Adenocarcinoma of the Prostate

Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer

Start date: December 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying sorafenib tosylate and gene expression in patients undergoing surgery for high-risk localized prostate cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Studying samples of blood and tumor tissues in the laboratory from patients with prostate cancer may help doctors learn more about changes that occur in DNA after treatment with sorafenib tosylate

NCT ID: NCT00464893 Completed - Gastric Cancer Clinical Trials

Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection

Start date: April 2007
Phase: Phase 2
Study type: Interventional

Primary evaluation of the safety, tolerability and feasibility regarding specific postoperative complications of an adjuvant treatment with catumaxomab administered after curative tumor resection subsequent to a neoadjuvant chemotherapy.

NCT ID: NCT00462553 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors

Start date: March 2007
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of sunitinib and gemcitabine in treating patients with pancreatic cancer or other solid tumors. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in hemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sunitinib together with gemcitabine may kill more tumor cells.

NCT ID: NCT00460356 Completed - Clinical trials for Cervical Adenocarcinoma

Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes

Start date: April 2, 2007
Phase: N/A
Study type: Observational

This clinical trial studies glycoprotein and glycan in tissue and blood samples of patients with stage IB-IVA cervical cancer undergoing surgery to remove pelvic and abdominal lymph nodes. Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer. It may also help doctors learn how far the disease has spread.

NCT ID: NCT00459407 Completed - Clinical trials for Adenocarcinoma of the Prostate

Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate

Start date: March 2007
Phase: Phase 1
Study type: Interventional

Green tea extract contains ingredients that may prevent or slow the growth of prostate cancer. This phase I trial is studying how well green tea extract works in treating patients with prostate cancer undergoing surgery to remove the prostate

NCT ID: NCT00456716 Completed - Lung Cancer Clinical Trials

Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma

Start date: March 2007
Phase: Phase 2
Study type: Interventional

Open label study of sorafenib